AP3B2

Across TCGA pan-cancer cohorts, AP3B2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP3B2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AP3B2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3B2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where AP3B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.418	1.000	.020	26	view →
CCRCC	DFS	Median	All	0.340	1.000	.014	6	view →
PDAC	DFS	Tertile	III,IV	0.674	0.211	.016	5	view →
LSCC	OS	Quartile	III,IV	0.510	0.901	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AP3B2–UCEC (DFS)

Open the UCEC breakdown →